ProLung announces corporate name change to IONIQ Sciences to reflect expanded early cancer detection strategy
In News
Salt Lake City, UT, May 27, 2020 – IONIQ Sciences Inc. (“IONIQ Sciences” or the...
Read More
ProLung Announces Fully Subscribed Private Placement of $3.3 Million
In News
Salt Lake City, UT, May 22, 2020 – ProLung, Inc. (“ProLung” or the “Company”), which has...
Read More
ProLung, Inc. Called One of the “50 Most Innovative Companies to Watch in 2020” by CEO Views
ProLung, Inc. is proud to announce it is one of the “50 Most Innovative Companies...
Read More
ProLung Test is honored as “Most Innovative Non-Invasive Lung Cancer Testing Solution 2020” by Global Health & Pharma
ProLung has been awarded the “Most Innovative Non-Invasive Lung Cancer Testing Solution 2020” by Global...
Read More
In Their Words: Jared Bauer
In Their Words: Jared Bauer Utah has an incredibly strong life sciences community with a rich...
Read More
ProLung Test Granted ‘Breakthrough Device’ Designation by the FDA
ProLung Test Granted ‘Breakthrough Device’ Designation by the FDA Salt Lake City, UT, February 13, 2020...
Read MoreProLung Announces End of 2012-2014 Governance Issues
In News
ProLung Announces End of 2012-2014 Governance Issues Salt Lake City, UT, February 13, 2020 – ProLung,...
Read MoreCEO Today Magazine Honors ProLung CEO Jared Bauer for Leadership and Strategic Vision in 2019
We are delighted to share that Jared Bauer, ProLung CEO, has been honored for his...
Read MoreProLung Announces Change to its Board of Directors
In News
ProLung Announces Change to its Board of Directors Salt Lake City, UT, November 26, 2019 –...
Read MoreProLung, Inc. presents highest combined sensitivity and specificity values for a truly non-invasive lung cancer solution pursuing FDA clearance at ISRD & ATS joint medical conference
In News
ProLung, Inc. presents highest combined sensitivity and specificity values for a truly non-invasive lung cancer...
Read MoreProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 74% specificity
In News
ProLung, Inc. Announces Large Clinical Validation Trial Results of 84% sensitivity and 73% specificity Salt Lake...
Read More
ProLung Promotes Jared Bauer from interim CEO to CEO
In News
ProLung Promotes Jared Bauer from interim CEO to CEO Salt Lake City, UT, October 2, 2019...
Read More